Attitudes and Unmet Needs Among Type 2 Diabetes Patients

The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes (T2D) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. Study participants will be recruited to complete a 15-minute self-administered online survey.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site, Sydney, Australia

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, age above or equal between 18 to 65 years at the time of signing informed consent.
Diagnosed with T2D and currently treating T2D with at least one medication
Insulin user that is not using insulin pump
Lives in a target country

Exclusion criteria

Previous participation in this study. Participation is defined as having given informed consent in this study
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Does not meet inclusion criteria requirements

Treatment and study plan

No treatment given

Other

No treatment given

Primary outcomes

Current medication burden

Time frame: At the time of survey response (Day1)

Numerical; Multiple select from defined list
Injection perceptions

Time frame: At the time of survey response (Day1)

Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"
Attitudes regarding T2D overall

Time frame: At the time of survey response (Day1)

Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree"
Attitudes regarding T2D treatment

Time frame: At the time of survey response (Day1)

Likert scales for measurement of satisfaction from 1 "extremely unsatisfied" to 7 "extremely satisfied" and agreement from 1 "strongly disagree" to 7 "strongly agree"
Attitudes regarding insulin icodec

Time frame: At the time of survey response (Day1)

Likert scales for measurement of likelihood from 0 "not at all likely" to 10" extremely likely" and agreement from 1 "strongly disagree" to 7 "strongly agree; Rank top 3 from defined list

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Feb 21, 2023
Registry last updated: May 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed